Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Pioglitazone slows progression of atherosclerosis in diabetes patients

  • Comment
Diabetes patients treated with the drug pioglitazone experience a significantly lower rate of progression of atherosclerosis compared with those treated with glimepiride, research has shown.
Findings were based on a study of 543 patients who were randomly treated with either pioglitazone or glimepiride in 97 North and South American hospitals for 18 months.

Percentage atheroma volumes (PAV) were measured at the start and end of the study.

Results showed PAV increased by 0.73% in the glimepiride group but decreased by 0.16% in the pioglitizone patients.

Journal of the American Medical Association (2008) 299:1561-1573
  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.